Psilocybin and aging: promising or too early to cheer?

A recent study suggests that psilocybin may affect cellular aging and survival in mice, which has attracted much attention. While the results at the cellular level and in animal models are interesting, there is no evidence that these effects also occur in humans. Experts stress that the research is promising, but for now too limited and speculative to consider psilocybin as an anti-aging intervention.

Renewed interest in psilocybin, the active ingredient in so-called "magic mushrooms," is growing rapidly. Whereas it was long known primarily as a psychedelic drug, today it is being explored within clinical settings for depression, anxiety disorders and addiction treatment, among others.

A recent study by Kato et al. drew additional attention by suggesting that psilocybin may affect cellular aging. That sounds almost too good to be true. Therefore, it is important to look critically at what this study does and does not show.

What did the study examine?

The researchers looked at the effects of psilocin, the active form of psilocybin, in both cell culture and animal models.

1. Studies in cell culture

The following effects were observed in human lung fibroblasts:

• Cells divided 29% longer before aging occurred
• At higher doses even up to 57% longer
• Decrease in oxidative stress (less ROS production)
• Less telomere damage

These results seem impressive, but these are isolated cells in a laboratory dish, not a complete human organism.

2. Research in mice

Thirty older female mice were administered psilocybin monthly. After ten months:

• Were 80% of the psilocybin group still alive
• Compared to 50% of the control group
• The treated mice seemed more vital, with smoother fur and less gray

Intriguing findings, but this does not yet constitute evidence of anti-aging effects in humans.

Why are experts critical?

Among others, physician and longevity researcher Peter Attia makes important comments on the interpretation of this study.

Limitations of the telomere hypothesis

The study suggests that telomere length plays a role in the aging process. In practice, however, telomere length does not appear to be a reliable predictor of longevity in humans or animals. The relationship is weak and not causally demonstrated.

No full life span study

The mouse experiment stopped once 50% of the control group had died. As a result, it is unknown whether psilocybin extends maximum lifespan or only temporarily delays mortality.

Dosage issue

The doses used in mice, converted, are considerably higher than what humans receive in clinical trials. That makes a direct translation to safety or effectiveness in humans uncertain.

Uncertain mechanisms of action

Less oxidative stress, less inflammation, direct cellular effects or indirect influence via stress reduction and neurobiology: for now, these are hypotheses, not proven mechanisms.

What does this research mean?

The study opens up an interesting line of research: whether mental health and stress regulation can affect biological aging. That idea is not new, but psilocybin makes it more measurable within research.

What we can state at this time:

• The biochemical effects on cells are interesting
• Survival data in mice are promising but limited
• The evidence is too early and too basic for conclusions in humans

Psilocybin is thus not yet an anti-aging intervention, but it is a candidate for further basic research.

What is important to follow?

Future research will have to show:

• Whether the effects are reproducible in larger animal models
• Whether there are biological effects without hallucinations
• Which doses are safe in the long term
• Whether people actually experience slower biological aging

Until then, psilocybin remains mostly promising in theory, but unproven in practice.